Acute eosinophilic pneumonia associated with 2009 influenza A (H1N1)

Eun Ju Jeon,1 Kwang Hyun Kim,2 Kyung Hoon Min2

ABSTRACT
Acute eosinophilic pneumonia (AEP) is a cause of acute respiratory failure, and differs from other eosinophilic pneumonias by its acute onset, presence of fever and acute hypoxaemia. Cases of 2009 influenza A (H1N1) virus infection have included rapidly progressive lower respiratory tract disease resulting in respiratory failure. We describe the case of a young patient who showed dyspnoea, fever and rapid radiological progression and was simultaneously diagnosed with AEP and 2009 influenza A (H1N1) infection, which was diagnosed by using bronchoalveolar lavage (BAL). We suggest that 2009 influenza A (H1N1) virus should be considered as a cause of AEP, and BAL can provide further information, especially in patients with severe lower respiratory disease.

A 20-year-old man was admitted to a nearby hospital with symptoms including fever (38.5°C), dyspnoea and chest discomfort for 2 days. He had no history of smoking, drug use or exposure to dust and disease, such as allergies or HIV infection. Chest auscultation revealed inspiratory crackles in both lower lung fields. A chest radiograph and CT showed ill-defined ground-glass opacities with interlobular septal thickening and minimal bilateral pleural effusion (figure 1A,B). The patient’s arterial blood gas analysis was pH 7.46, PaO2 70 mm Hg, PaCO2 36.2 mm Hg and 95% O2 saturation. The results of other laboratory tests revealed white blood cells 13.0 × 10⁹/l (neutrophils 75%, lymphocytes 14.2%, monocytes 8.6% and eosinophils 4.2%) and C-reactive protein 7.2 mg/dl. The clinician prescribed oseltamivir (75 mg twice daily) and obtained reactive protein 7.2 mg/dl. The clinician prescribed oseltamivir (75 mg twice daily) and obtained reactive protein 7.2 mg/dl. The clinician prescribed oseltamivir (75 mg twice daily) and obtained reactive protein 7.2 mg/dl. The clinician prescribed oseltamivir (75 mg twice daily) and obtained reactive protein 7.2 mg/dl. The clinician prescribed oseltamivir (75 mg twice daily) and obtained reactive protein 7.2 mg/dl. The clinician prescribed oseltamivir (75 mg twice daily) and obtained reactive protein 7.2 mg/dl. The clinician prescribed oseltamivir (75 mg twice daily) and obtained reactive protein 7.2 mg/dl. The clinician prescribed oseltamivir (75 mg twice daily) and obtained reactive protein 7.2 mg/dl. The clinician prescribed oseltamivir (75 mg twice daily) and obtained reactive protein 7.2 mg/dl. The clinician prescribed oseltamivir (75 mg twice daily) and obtained reactive protein 7.2 mg/dl.

DISCUSSION
AEP is an acute febrile respiratory illness with severe hypoxaemia, diffuse pulmonary infiltrates and an increase in BAL eosinophils. One study has suggested that AEP is an acute hypersensitivity reaction to an unidentified inhaled antigen.1 The following observations are consistent with this hypothesis. Onset of cigarette smoking, alterations in smoking habits, unusual outdoor activities and inhalation of cocaine or heroin are the known reported causes.2–5 There is also evidence that some infections can cause AEP. In patients who received lung allografts, AEP was attributed to Aspergillus species, coxsackie A2 virus and Pseudomonas maltophilia.6 In the present case, we tried to exclude known possible causes of AEP. The patient had no history of allergic disease, smoking, drug use or exposure to dust. The tests for allergies, parasite infection, HIV infection and bacterial infection were all negative, and there was no peripheral eosinophilia. Consequently, the only one possible cause of AEP was 2009 influenza A (H1N1).

2009 influenza A (H1N1) virus has emerged to cause the first pandemic of the 21st century, and can cause acute respiratory distress syndrome in previously healthy persons.8 In most cases, 2009 influenza A (H1N1) virus is confirmed by using an RT–PCR test that is performed on a swab obtained from the upper respiratory tract. The performance of RT–PCR assays specific for 2009 influenza A (H1N1) has not been established for BAL and tracheal aspirates. However, the US Centers for Disease Control and Prevention recommends that lower respiratory tract specimens should be collected and tested to improve diagnostic yield in patients with severe lower respiratory disease (eg, suspected viral pneumonia) who are intubated or undergoing bronchoscopy.9 One report has demonstrated that investigators assayed 21 patients who...
were confirmed as having 2009 influenza A (H1N1) infection. Investigators obtained upper respiratory tract specimens from the nose or throat, and lower respiratory tract specimens using bronchoscopy. Specimens from the lower respiratory tract were positive for 2009 influenza A (H1N1) in all patients when tested with RT-PCR, but specimens from the upper respiratory tract were positive in only 17 of 21 patients (81%). In accordance with this previous study, our present case showed that RT-PCR was only positive in the lower respiratory tract specimen.

Although the patient in this report received oseltamivir, if a lower respiratory tract specimen had not been obtained we could not have confirmed the cause of acute febrile lower respiratory disease.

To our knowledge, this is the first report of AEP associated with 2009 influenza A (H1N1). We conclude that 2009 influenza A (H1N1) virus should be considered as a cause of AEP. Although BAL is not the essential specimen for study in the diagnosis of all patients presenting with suspected 2009 influenza A (H1N1), it

Figure 1 (A) Chest radiograph on admission showed mixed reticular and ground-glass opacity on both mid and lower lung fields with bilateral blunting of the costophrenic angles. (B) Chest CT showed ill-defined ground-glass opacities with interlobular septal thickening and minimal bilateral pleural effusion. (C) Chest radiograph on 1 day after admission showed further aggravation of the pulmonary lesion. (D) Chest radiograph on the day of discharge showed complete resolution of the pulmonary lesion.

Figure 2 Centrifuged preparation of the bronchoalveolar lavage (BAL) fluid. Eosinophils accounted for 39% of the total cells (Diff-Quik stain, A: ×200, B: ×400).
can provide further information for clinicians, especially in patients with severe lower respiratory disease.

**Competing interests** None.

**Patient consent** Obtained.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**REFERENCES**


**Pulmonary puzzle**

**ANSWER**

From the question on page 214

Churg-Strauss syndrome (CSS) was diagnosed on the basis of extensive vasculitis in a sural nerve biopsy, tissue eosinophilia in a cecum biopsy (see figure in online supplement) and peripheral eosinophilia (11%, observed only once). The cecum biopsy was performed because anaemia had become microcytic; pathological analysis was consistent with an eosinophilic gastroenteritis. P-Antineutrophil cytoplasmic antibody (titre 1:1280) and ant-myeloperoxidase (657 U/ml) antibodies were strongly positive. CSS disease activity markers soluble interleukin-2 receptor (7748 pg/ml) and eosinophilic cationic protein (13.2 mg/l) were elevated.

There was no history of the use of antileukotriene agents or acetaminophen. Although no single CT image is pathognomonic for CSS, ground-glass attenuation appears to be the most consistent feature. Pulmonary fibrosis is not usually mentioned as a complication of CSS but has been reported previously and may represent the final common pathway of untreated disease.

The following points can be learnt from this case. CSS can present with symptoms resembling rheumatoid arthritis but joint involvement is not usually mentioned as a manifestation of CSS. CSS may be present without a formal diagnosis of asthma because pulmonary vascular disease can also be characterised by low diffusing capacity without obstruction. Limited testing for polynuropathy in the context of diabetes mellitus is usually recommended. However, severe pain, asymmetry and predominant or progressive motor symptoms (eventually all present in this patient) should serve as red flags and warrant further testing. Early recognition of CSS is important because treatment may stop the potentially dangerous progression of disease and reverse symptoms. In that regard, the presence of allergic rhinitis should have served as a diagnostic clue. Continuous low-dose steroid treatment may have disguised other diagnostic clues such as eosinophilia in blood and lavage fluid. Instead, a bronchoscopic or surgical lung biopsy early in the course may have expedited diagnosis. This case vividly demonstrates one of medicine’s challenges—the necessity to search for all possible diagnoses to avoid missing one, but also to avoid missing a single unifying diagnosis during this search. This case also illustrates the pitfalls of subspecialisation. The rheumatologist, respiratory physician and neurologist found alternative explanations for the patient’s concerns, obscuring the larger picture.

The patient was treated with prednisone (50 mg daily) and azathioprine (100 mg daily). Fever did not return, polyneuropathy improved and erythrocyte sedimentation rate, C-reactive protein and haemoglobin normalised.

Supplementary figure is published online only at http://thx.bmj.com/content/vol65/issue3.

**REFERENCES**

Acute eosinophilic pneumonia associated with 2009 influenza A (H1N1)

Eun Ju Jeon, Kwang Hyun Kim and Kyung Hoon Min

Thorax 2010 65: 268-270
doi: 10.1136/thx.2009.133025

Updated information and services can be found at:
http://thorax.bmj.com/content/65/3/268

These include:

References
This article cites 9 articles, 1 of which you can access for free at:
http://thorax.bmj.com/content/65/3/268#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Pulmonary eosinophilia (14)
- Influenza (106)
- TB and other respiratory infections (1273)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/